Sphera Funds Management LTD. increased its holdings in shares of Aldeyra Therapeutics Inc (NASDAQ:ALDX) by 19.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,044,131 shares of the biotechnology company’s stock after acquiring an additional 168,200 shares during the period. Aldeyra Therapeutics makes up approximately 1.1% of Sphera Funds Management LTD.’s portfolio, making the stock its 19th biggest holding. Sphera Funds Management LTD. owned 5.61% of Aldeyra Therapeutics worth $7,518,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Bank of New York Mellon Corp acquired a new position in Aldeyra Therapeutics during the third quarter worth $134,000. Virtu KCG Holdings LLC purchased a new position in Aldeyra Therapeutics during the second quarter worth about $104,000. Renaissance Technologies LLC purchased a new position in Aldeyra Therapeutics during the first quarter worth about $132,000. Hikari Power Ltd lifted its position in Aldeyra Therapeutics by 186.4% during the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after buying an additional 70,196 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after purchasing an additional 9,407 shares during the period. 48.00% of the stock is currently owned by hedge funds and other institutional investors.
In related news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 19th. The shares were acquired at an average cost of $7.25 per share, for a total transaction of $1,450,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 19.04% of the company’s stock.
Shares of Aldeyra Therapeutics Inc (NASDAQ ALDX) opened at $6.95 on Friday. Aldeyra Therapeutics Inc has a 12 month low of $3.80 and a 12 month high of $11.90. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.35 and a current ratio of 20.35.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.09. sell-side analysts predict that Aldeyra Therapeutics Inc will post -1.39 EPS for the current year.
A number of research firms have recently commented on ALDX. ValuEngine downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Zacks Investment Research downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Cowen reiterated an “outperform” rating and issued a $14.00 target price (up previously from $9.00) on shares of Aldeyra Therapeutics in a research note on Thursday, September 14th. Cantor Fitzgerald assumed coverage on Aldeyra Therapeutics in a research note on Tuesday, October 24th. They set an “overweight” rating and a $22.00 price objective for the company. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $27.00 target price (up previously from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.29.
TRADEMARK VIOLATION WARNING: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://ledgergazette.com/2017/12/09/sphera-funds-management-ltd-boosts-position-in-aldeyra-therapeutics-inc-aldx.html.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.